APLMW (Apollomics) Effective Interest Rate on Debt %: 8.65% (As of Dec. 2025)


APLMW Apollomics Inc APLMW
30 GF Score
Price $0.01
! 4 Warning Signs
View Full Analysis

What is Apollomics Effective Interest Rate on Debt %?

Apollomics APLMW -13.22% 30 Effective Interest Rate on Debt % is 8.65% as of Dec. 2025. GuruFocus rates APLMW with a GF Score™ of 30/100. The stock has 4 warning signs investors should review.

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Apollomics's annualized positive value of Interest Expense for the quarter that ended in Dec. 2025 was $0.06 Mil. Apollomics's average total debt for the quarter that ended in Dec. 2025 was $0.69 Mil. Therefore, Apollomics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2025 was 8.65%.

Apollomics  (NAS:APLMW) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Apollomics Effective Interest Rate on Debt % Related Terms

Apollomics Effective Interest Rate on Debt % Historical Data

* Premium members only.

The historical data trend for Apollomics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apollomics Effective Interest Rate on Debt % Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Effective Interest Rate on Debt %
Get a 7-Day Free Trial 6.52 9.18 5.31 6.36 8.08

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 6.74 5.71 3.16 8.19 8.65

APLMW vs HYPD, MGX, KALA: Effective Interest Rate on Debt % Comparison

For the Biotechnology subindustry, Apollomics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apollomics Effective Interest Rate on Debt % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apollomics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Apollomics's Effective Interest Rate on Debt % falls into.


APLMW
30GF Score
Apollomics Inc APLMW
Effective Interest Rate on Debt % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apollomics Effective Interest Rate on Debt % Calculation

Apollomics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2024 )+Total Debt  (A: Dec. 2025 ))/ count )
=-1  *  -0.065/( (0.966+0.643)/ 2 )
=-1  *  -0.065/0.8045
=8.08 %

where

Total Debt  (A: Dec. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.733 + 0.233
=0.966

Total Debt  (A: Dec. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.434 + 0.209
=0.643

Apollomics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Jun. 2025 )+Total Debt  (Q: Dec. 2025 ))/ count )
=-1  *  -0.06/( (0.744+0.643)/ 2 )
=-1  *  -0.06/0.6935
=8.65 %

where

Total Debt  (Q: Jun. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.541 + 0.203
=0.744

Total Debt  (Q: Dec. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.434 + 0.209
=0.643

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is two times the semi-annual (Dec. 2025) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

What does a Effective Interest Rate on Debt % of 8.65% mean?
Apollomics (APLMW) has a Effective Interest Rate on Debt % of 8.65% as of Dec. 2025. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Apollomics and its competitors.
Is Apollomics' Effective Interest Rate on Debt % too high?
Apollomics' current Effective Interest Rate on Debt % is 8.65%. Overall, Apollomics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Apollomics' Effective Interest Rate on Debt % compare to HYPD and MGX?
Apollomics' Effective Interest Rate on Debt % of 8.65% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Biotechnology company?
A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Apollomics and its competitors. Apollomics's current Effective Interest Rate on Debt % is 8.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apollomics stock overvalued right now?
Apollomics (APLMW) has a current Effective Interest Rate on Debt % of 8.65%. The current Effective Interest Rate on Debt % is 8.65%. Apollomics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Apollomics (APLMW), the current Effective Interest Rate on Debt % is 8.65% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apollomics Business Description

Other Exchanges APLM:USA
Address 989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
30GF Score

Get the complete analysis for APLMW

Effective Interest Rate on Debt % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price